Idiopathic CD4+ Lymphocytopenia Pipeline Insights, 2019 Report – Development Activities, Analytical Perspective, Product Assessment – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Idiopathic CD4+ Lymphocytopenia – Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Idiopathic CD4+ Lymphocytopenia – Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication.

A detailed picture of the Idiopathic CD4+ Lymphocytopenia pipeline landscape is provided which includes the disease overview and Idiopathic CD4+ Lymphocytopenia treatment guidelines. The assessment part of the report embraces, in depth Idiopathic CD4+ Lymphocytopenia commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Idiopathic CD4+ Lymphocytopenia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Idiopathic CD4+ Lymphocytopenia Pipeline Development Activities

The Report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Idiopathic CD4+ Lymphocytopenia targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Idiopathic CD4+ Lymphocytopenia pipeline report covers 3+ companies. Some of the key players include NeoImmuneTech (Hyleukin-7) etc.

Idiopathic CD4+ Lymphocytopenia Analytical Perspective

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Idiopathic CD4+ Lymphocytopenia Clinical Assessment of products

The Report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Key Topics Covered:

1. Report Introduction

2. Idiopathic CD4+ Lymphocytopenia

2.1. Idiopathic CD4+ Lymphocytopenia Disease Overview

2.2. Idiopathic CD4+ Lymphocytopenia History

2.3. Idiopathic CD4+ Lymphocytopenia Symptoms

2.4. Idiopathic CD4+ Lymphocytopenia Causes

2.5. Idiopathic CD4+ Lymphocytopenia Pathophysiology

2.6. Idiopathic CD4+ Lymphocytopenia Diagnosis

2.6.1. Diagnostic Guidelines

3. Idiopathic CD4+ Lymphocytopenia Current Treatment Patterns

3.1. Treatment Guidelines

4. Idiopathic CD4+ Lymphocytopenia- Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Idiopathic CD4+ Lymphocytopenia companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Idiopathic CD4+ Lymphocytopenia Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis

4.1.2.2. Idiopathic CD4+ Lymphocytopenia Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono / Combination)

4.2.2.1. Assessment by Stage and Product Type

4.2.3. Assessment by Route of Administration

4.2.3.1. Assessment by Stage and Route of Administration

4.2.4. Assessment by Molecule Type

4.2.4.1. Assessment by Stage and Molecule Type

4.2.5. Assessment by MOA

4.2.5.1. Assessment by Stage and MOA

5. Idiopathic CD4+ Lymphocytopenia Pipeline Therapeutics

5.1. Late Stage Products (Phase-III)

5.1.1. Comparative Analysis

5.2. Mid Stage Products (Phase-II)

5.2.1. Comparative Analysis

5.3. Early Stage Products (Phase-I)

5.3.1. Comparative Analysis

5.4. Pre-clinical and Discovery Stage Products

5.4.1. Comparative Analysis

5.5. Inactive Products

6. Idiopathic CD4+ Lymphocytopenia-Products Analysis

6.1. Product Profiles

6.1.1. Hyleukin-7- NeoImmuneTech

6.1.1.1. Product Description

6.1.1.1.1. Product Overview

6.1.1.1.2. Mechanism of Action

6.1.1.2. Research and Development

6.1.1.2.1. Clinical Studies

6.1.1.2.1.1. Detailed Study Description

6.1.1.2.1.2. Study Results

6.1.1.2.1.3. Clinical Trials: Tabular View

6.1.1.3. Product Development Activities

6.1.1.3.1. Tabulated Product Summary

6.1.1.3.1.1. General Description Table

7. Recent Technologies

8. Idiopathic CD4+ Lymphocytopenia Key Companies

8.1. Revimmune SAS

8.2. Genexine

8.3. NeoImmuneTech

9. Idiopathic CD4+ Lymphocytopenia Key Products

9.1. Interleukin 7

9.2. Efineptakin alfa

9.3. Hyleukin-7

10. Dormant and Discontinued Products

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. Idiopathic CD4+ Lymphocytopenia- Unmet Needs

12. Idiopathic CD4+ Lymphocytopenia- Future Perspectives

13. Appendix

Companies Mentioned

• Revimmune SAS
• Genexine
• Merck & Co
• Biogen Idec
• Millennium Pharmaceuticals
• Ono Pharmaceutical
• Chiron
• Bayer
• Sanofi

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/dualjt

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900